{"disease":{"id":"spasticity","name":"Spasticity","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":13,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"onabotulinumtoxina","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Botox","generic_name":"ONABOTULINUMTOXINA","company_name":"Allergan","drug_phase":"marketed","molecular_target":"SNAP-25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":60,"revenue":"5300","mechanism":"BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25."},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in pediatric patients (excluding cerebral palsy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"diazepam","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valium","generic_name":"diazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sativex","indication_name":"Muscle Spasticity due to Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sativex","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"chlorphenesin-carbamate","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maolate","generic_name":"CHLORPHENESIN CARBAMATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"botulinum-toxin-type-a","indication_name":"Lower limb spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."},{"drug_id":"botulinum-toxin-type-a","indication_name":"Upper limb spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."},{"drug_id":"methocarbamol","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Robaxin","generic_name":"METHOCARBAMOL","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1","drug_class":"Muscle Relaxant [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"metaxalone","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skelaxin","generic_name":"METAXALONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Muscle Relaxant [EPC]","quality_score":55,"revenue":null,"mechanism":"Skelaxin works by inhibiting the action of neurotransmitters that stimulate muscle contraction."},{"drug_id":"orphenadrine","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norflex","generic_name":"ORPHENADRINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Muscle Relaxant","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"caffeine","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tizanidine","indication_name":"Muscle Spasticity of Cerebral Origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanaflex","generic_name":"TIZANIDINE","company_name":"Legacy Pharma Usa","drug_phase":"marketed","molecular_target":"Nischarin","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"tizanidine","indication_name":"Muscle spasticity of spinal origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanaflex","generic_name":"TIZANIDINE","company_name":"Legacy Pharma Usa","drug_phase":"marketed","molecular_target":"Nischarin","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"tizanidine","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanaflex","generic_name":"TIZANIDINE","company_name":"Legacy Pharma Usa","drug_phase":"marketed","molecular_target":"Nischarin","drug_class":"Central alpha-2 Adrenergic Agonist","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"cannabinoids","indication_name":"Muscle Spasticity due to Multiple Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cannabinoids","company_name":"New York State Psychiatric Institute","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"carisoprodol","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Soma","generic_name":"CARISOPRODOL","company_name":"Mylan Speciality Lp","drug_phase":"marketed","molecular_target":"","drug_class":"Muscle Relaxant [EPC]","quality_score":59,"revenue":null,"mechanism":"Carisoprodol's mechanism for relieving acute musculoskeletal pain is unclear, but it involves altered interneuronal activity in the spinal cord and brain."},{"drug_id":"dantrolene","indication_name":"Muscle Spasticity of Cerebral Origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ryanodex","generic_name":"DANTROLENE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Ryanodine receptor 1","drug_class":"Skeletal Muscle Relaxant","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"dantrolene","indication_name":"Muscle spasticity of spinal origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ryanodex","generic_name":"DANTROLENE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Ryanodine receptor 1","drug_class":"Skeletal Muscle Relaxant","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"dantrolene","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ryanodex","generic_name":"DANTROLENE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Ryanodine receptor 1","drug_class":"Skeletal Muscle Relaxant","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"chlorzoxazone","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parafon Forte Dsc","generic_name":"CHLORZOXAZONE","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Nitric oxide synthase, endothelial","drug_class":"Muscle Relaxant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"incobotulinumtoxina","indication_name":"Spasticity caused by cerebral palsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"baclofen","indication_name":"Muscle Spasticity of Cerebral Origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lioresal","generic_name":"BACLOFEN","company_name":"","drug_phase":"marketed","molecular_target":"GABA-B receptor","drug_class":"gamma-Aminobutyric Acid-ergic Agonist [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"baclofen","indication_name":"Muscle spasticity of spinal origin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lioresal","generic_name":"BACLOFEN","company_name":"","drug_phase":"marketed","molecular_target":"GABA-B receptor","drug_class":"gamma-Aminobutyric Acid-ergic Agonist [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"cyclobenzaprine","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amrix","generic_name":"CYCLOBENZAPRINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Muscle Relaxant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"incobotulinumtoxina","indication_name":"Upper limb spasticity in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"thiocolchicoside","indication_name":"Spasticity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Muscoril","generic_name":"THIOCOLCHICOSIDE","company_name":"","drug_phase":"phase_3","molecular_target":"GABA A receptor alpha-1/beta-1/gamma-2, GABA A receptor alpha-2/beta-2/gamma-2, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":28,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03047369","title":"The Myelin Disorders Biorepository Project","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT06055725","title":"A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1058,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03999788","title":"miR-142-3p as Potential Biomarker of Synaptopathy in MS","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Neuromed IRCCS","has_results":false},{"nct_id":"NCT05379413","title":"Observational Longitudinal Study on the Outbreak and Management of Stroke Related Spasticity","phase":"","overall_status":"UNKNOWN","enrollment_count":960,"lead_sponsor_name":"Campus Bio-Medico University","has_results":false},{"nct_id":"NCT03660969","title":"Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal Muscle Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":797,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT01930786","title":"An Adult Spasticity Registry of OnabotulinumtoxinA Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":744,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT03588832","title":"Prevalence of Postural Patterns of Upper Extremity.","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Universidad de La Frontera","has_results":false},{"nct_id":"NCT03290131","title":"A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":536,"lead_sponsor_name":"RVL Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07504627","title":"How Stroke Affects Leg Muscles When Walking","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT04936542","title":"A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":464,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04649632","title":"Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.","phase":"","overall_status":"COMPLETED","enrollment_count":451,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04050527","title":"Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":438,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03756974","title":"BX-1 in Spasticity Due to Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"Bionorica SE","has_results":false},{"nct_id":"NCT01457352","title":"Efficacy and Safety of SPARC0921 in Subjects With Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":392,"lead_sponsor_name":"Sun Pharma Advanced Research Company Limited","has_results":true},{"nct_id":"NCT01603628","title":"BOTOX® Treatment in Pediatric Lower Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":384,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT01603641","title":"BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT02002884","title":"Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"Merz Pharmaceuticals GmbH","has_results":true},{"nct_id":"NCT03319732","title":"A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"RVL Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07478822","title":"A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Chongqing Claruvis Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06958341","title":"Neuroimmunology Registry and Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT04815967","title":"Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":272,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06783114","title":"A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":254,"lead_sponsor_name":"Chongqing Claruvis Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03017729","title":"Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity","phase":"","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04752774","title":"A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT02699190","title":"LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies","phase":"","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":true},{"nct_id":"NCT01603602","title":"BOTOX® Treatment in Pediatric Upper Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT01603615","title":"BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03289702","title":"CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT04714385","title":"Medtronic PSR TDD PMCF","phase":"","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Medtronic","has_results":false},{"nct_id":"NCT05354622","title":"Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Boston Children's Hospital","has_results":false},{"nct_id":"NCT06811142","title":"Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Instituto Mexicano del Seguro Social","has_results":false},{"nct_id":"NCT06782490","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04446702","title":"Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinA","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05289921","title":"To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Huons Co., Ltd.","has_results":false},{"nct_id":"NCT05506228","title":"How Are the Muscles Affected in Cerebral Palsy? A Study of Muscle Biopsies Taken During Orthopaedic Surgery.","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Eva Ponten","has_results":false},{"nct_id":"NCT05518565","title":"The Muscle in Cerebral Palsy; Sarcomere Length in Vivo and Microscopic Characterization of Biopsies.","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Eva Ponten","has_results":false},{"nct_id":"NCT04340336","title":"Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type A","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT02027025","title":"Study of SPARC1103 in Subjects With Spasticity","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Sun Pharma Advanced Research Company Limited","has_results":true},{"nct_id":"NCT03261167","title":"A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03462693","title":"Dry Needling in Stroke in Sub-Acute Phase to Improve Upper Limb","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Guadarrama Hospital","has_results":false},{"nct_id":"NCT04604379","title":"A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal Spasticity","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05224349","title":"Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.","phase":"","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03908580","title":"MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT06726434","title":"Evaluation of Percutaneous Cryoneurotomy Compared to Surgical Open Neurotomy for the Management of Equinovarus Foot Deformity in Patients With Refractory Lower Limb Spasticity After Stroke","phase":"NA","overall_status":"RECRUITING","enrollment_count":114,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT04396704","title":"A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05965713","title":"National Fully Remote Use of IpsiHand Device in Hemiparetic Stroke","phase":"NA","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Neurolutions, Inc.","has_results":false},{"nct_id":"NCT06150729","title":"Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy","phase":"","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT05103202","title":"Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin","phase":"","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03442660","title":"Validation of the Spasticity Related Quality of Life Questionnaire","phase":"NA","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT06706063","title":"Ultrasonograpy in Hemiplegic Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Afyonkarahisar Health Sciences University","has_results":false}],"total":50},"guidelines":[{"drug_id":"diazepam","guideline_body":"FDA label","recommendation":"Diazepam tablets are a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome.","line_of_therapy":"adj","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}